tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VRDN Stock Latest News

Viridian Therapeutics: Well-Funded Late-Stage Pipeline and Imminent Phase 3 Catalysts Support Buy Rating and $42 Target
RatingsViridian Therapeutics: Well-Funded Late-Stage Pipeline and Imminent Phase 3 Catalysts Support Buy Rating and $42 Target
22h ago
VRDN
Viridian Therapeutics price target lowered to $42 from $45 at RBC Capital
PremiumThe Fly
Viridian Therapeutics price target lowered to $42 from $45 at RBC Capital
1d ago
VRDN
Viridian Therapeutics price target raised to $45 from $44 at Jefferies
PremiumThe Fly
Viridian Therapeutics price target raised to $45 from $44 at Jefferies
2d ago
VRDN
Viridian Therapeutics reports Q4 EPS ($1.08), consensus ($1.00)
PremiumThe Fly
Viridian Therapeutics reports Q4 EPS ($1.08), consensus ($1.00)
2d ago
VRDN
Strategic Buy on Viridian Therapeutics Ahead of Veligrotug PDUFA and Elegrobart Phase 3 REVEAL‑1 Readout
PremiumRatings
Strategic Buy on Viridian Therapeutics Ahead of Veligrotug PDUFA and Elegrobart Phase 3 REVEAL‑1 Readout
4d ago
VRDN
Needham biotech analysts hold an analyst/industry conference call
PremiumThe FlyNeedham biotech analysts hold an analyst/industry conference call
24d ago
VRDN
Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI
Premium
The Fly
Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI
1M ago
VRDN
Viridian Therapeutics initiated with a Buy at UBS
Premium
The Fly
Viridian Therapeutics initiated with a Buy at UBS
2M ago
VRDN
Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating
PremiumRatings
Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating
2M ago
VRDN
Viridian Therapeutics: 2026 Clinical and Regulatory Catalysts, Strong Balance Sheet Support Buy Rating on VRDN
PremiumRatings
Viridian Therapeutics: 2026 Clinical and Regulatory Catalysts, Strong Balance Sheet Support Buy Rating on VRDN
2M ago
VRDN
Viridian Therapeutics: Building a Best-in-Class Thyroid Disease Franchise with Multiple Clinical Catalysts Supporting a Buy Rating
PremiumRatings
Viridian Therapeutics: Building a Best-in-Class Thyroid Disease Franchise with Multiple Clinical Catalysts Supporting a Buy Rating
2M ago
VRDN
Viridian Therapeutics: Multiple 2026 Catalysts and Pipeline Momentum Underpin Buy Rating
PremiumRatings
Viridian Therapeutics: Multiple 2026 Catalysts and Pipeline Momentum Underpin Buy Rating
2M ago
VRDN
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating
PremiumRatingsViridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating
2M ago
VRDN
Viridian: Priority Review for Veligrotug and Catalyst-Rich 2026 Outlook Drive Price Target Raise and Buy Rating
Premium
Ratings
Viridian: Priority Review for Veligrotug and Catalyst-Rich 2026 Outlook Drive Price Target Raise and Buy Rating
2M ago
VRDN
Viridian announces FDA acceptance of veligrotug biologics license application
Premium
The Fly
Viridian announces FDA acceptance of veligrotug biologics license application
2M ago
VRDN
3 Stocks Flashing Strong Buy Signals, Backed by Technical Analysis
PremiumMarket News
3 Stocks Flashing Strong Buy Signals, Backed by Technical Analysis
2M ago
NGD
WVE
Viridian Therapeutics: Strong Market Position and Promising Catalysts Justify Buy Rating
PremiumRatings
Viridian Therapeutics: Strong Market Position and Promising Catalysts Justify Buy Rating
2M ago
VRDN
Viridian Therapeutics Positioned for Growth in TED Market Amidst Competitive Setbacks
PremiumRatings
Viridian Therapeutics Positioned for Growth in TED Market Amidst Competitive Setbacks
3M ago
VRDN
Argenx exit leaves more room for Viridian in TED, says Truist
PremiumThe Fly
Argenx exit leaves more room for Viridian in TED, says Truist
3M ago
ARGX
VRDN
Viridian Therapeutics rises 5.0%
PremiumThe FlyViridian Therapeutics rises 5.0%
3M ago
VRDN
Viridian Therapeutics: Positioned for Growth with Promising Pipeline and Strong Financials
Premium
Ratings
Viridian Therapeutics: Positioned for Growth with Promising Pipeline and Strong Financials
3M ago
VRDN
Viridian Therapeutics initiated with an Outperform at William Blair
Premium
The Fly
Viridian Therapeutics initiated with an Outperform at William Blair
3M ago
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >